The Drugs Controller General of India (DCGI) has issued a new set of guidelines, focusing on safety, immunogenicity and efficacy parameters for pharma giants who are developing COVID-19 vaccines.
from NDTV News - Topstories https://ift.tt/2EntxSq
Subscribe to:
Post Comments (Atom)
Will Tata Sons get listing waiver? RBI tweak will make it 'upper NBFC'
The Reserve Bank of India is proposing a simpler asset-size threshold of Rs 1 lakh crore to identify large NBFCs for stricter regulation, re...
-
China has emerged as a significant player in AI foundation models with DeepSeek, creating powerful AI models at lower costs than the West. T...
-
Nigeria's President Buhari on Sunday denied claims that he had died and been replaced by a Sudanese impostor, breaking his silence on a ...
-
from Business News Today: Stock Markets, Financial News, India Business & World Business News https://ift.tt/mGFIOle
No comments:
Post a Comment